dextromethorphan bupropion Auvelity
Selected indexed studies
- Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. (Clin Psychopharmacol Neurosci, 2023) [PMID:37859435]
- Auvelity (dextromethorphan/bupropion). (WMJ, 2023) [PMID:36724488]
- Dextromethorphan/Bupropion: First Approval. (CNS Drugs, 2022) [PMID:36301443]
_Worker-drafted node — pending editorial review._
Connections
dextromethorphan bupropion Auvelity is a side effect of
Sources
- Dextromethorphan/Bupropion: First Approval. (2022) pubmed
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Bupropion. (2006) pubmed
- Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. (2023) pubmed
- Auvelity (dextromethorphan/bupropion). (2023) pubmed
- Dextromethorphan/bupropion (Auvelity) for depression. (2022) pubmed
- Glutamatergic Modulators for Major Depression from Theory to Clinical Use. (2024) pubmed
- Dextromethorphan. (2006) pubmed
- Real-world signal detection of adverse events associated with Auvelity(bupropion-dextromethorphan): A pharmacovigilance study based on the FAERS database. (2025) pubmed
- Eco-friendly bupropion detection sensor with co-formulated dextromethorphan in AUVELITY tablet and spiked plasma. (2024) pubmed